S

SSY Group Ltd
HKEX:2005

Watchlist Manager
SSY Group Ltd
HKEX:2005
Watchlist
Price: 3.73 HKD -2.1% Market Closed
Market Cap: 11B HKD
Have any thoughts about
SSY Group Ltd?
Write Note

SSY Group Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

SSY Group Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
S
SSY Group Ltd
HKEX:2005
Total Liabilities & Equity
HK$12.5B
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
9%
G
Grand Pharmaceutical Group Ltd
HKEX:512
Total Liabilities & Equity
HK$24.9B
CAGR 3-Years
10%
CAGR 5-Years
13%
CAGR 10-Years
18%
U
United Laboratories International Holdings Ltd
HKEX:3933
Total Liabilities & Equity
ÂĄ22.8B
CAGR 3-Years
13%
CAGR 5-Years
8%
CAGR 10-Years
4%
Sino Biopharmaceutical Ltd
HKEX:1177
Total Liabilities & Equity
ÂĄ66.7B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
20%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Total Liabilities & Equity
HK$266.4B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Total Liabilities & Equity
$1.3B
CAGR 3-Years
0%
CAGR 5-Years
21%
CAGR 10-Years
19%
No Stocks Found

SSY Group Ltd
Glance View

Market Cap
11.1B HKD
Industry
Pharmaceuticals

SSY Group Ltd. is an investment holding company, which engages in the research, development, and manufacture of pharmaceutical products. The company employs 4,800 full-time employees The company went IPO on 2005-12-20. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.

Intrinsic Value
5.41 HKD
Undervaluation 31%
Intrinsic Value
Price
S

See Also

What is SSY Group Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
12.5B HKD

Based on the financial report for Jun 30, 2024, SSY Group Ltd's Total Liabilities & Equity amounts to 12.5B HKD.

What is SSY Group Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
9%

Over the last year, the Total Liabilities & Equity growth was 11%. The average annual Total Liabilities & Equity growth rates for SSY Group Ltd have been 9% over the past three years , 11% over the past five years , and 9% over the past ten years .

Back to Top